Illumina, ReaMetrix to collaborate on molecular diagnostics

By E. Janene Geiss

Philadelphia, July 20 - Illumina, Inc. and ReaMetrix, Inc. announced Thursday the formation of a diagnostic collaboration under which the companies plan to co-develop molecular diagnostic panels for a range of disease areas.

Under the agreement, ReaMetrix will gain non-exclusive rights to market the resulting panels in India. Illumina will retain rights to market the tests outside of India, according to a company news release.

Illumina said it will supply VeraCode technology and other reagents for the tests.

ReaMetrix said it will develop, validate and market diagnostic panels based on Illumina's upcoming BeadXpress platform, scheduled for market introduction before the end of 2006.

ReaMetrix will drive market development from its operation in Bangalore, India, officials said.

Illumina is a San Diego biopharmaceutical company.

ReaMetrix is a San Carlos, Calif., biopharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.